Abstracts Archive - Page 2066 of 2607 - ACR Meeting Abstracts

Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 2516 • 2014 ACR/ARHP Annual Meeting
Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
Kenya Terabe¹, Toshihisa Kojima¹, Nobunori Takahashi^1,2, Koji Funahashi³, Atsushi Kaneko⁴, Yuji Hirano⁵, Yasuhide Kanayama⁶, Yuichiro Yabe⁷ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²65 Tsurumai-cho, Showa-ku, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁷Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) patients who failed a first biologic agent due to any reasons have the option of switching to a second one along…
Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 2514 • 2014 ACR/ARHP Annual Meeting
Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Vittorio Grosso¹, Roberto Gorla², Piercarlo Sarzi-Puttini³, Fabiola Atzeni⁴, Raffaele Pellerito⁵, Enrico Fusaro⁶, Giuseppe Paolazzi⁷, Pier Andrea Rocchetta⁸, Ennio Giulio Favalli⁹, Antonio Marchesoni¹⁰ and Roberto Caporali¹¹, ¹Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²Reumatologia, Spedali Civili, Brescia, Italy, ³Rheumatology Unit, University Hospital L Sacco, Milano, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁵Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁶Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁷Rheumatology, Santa Chiara Hospital, Trento, Italy, ⁸Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, ¹¹Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose During the last fifteen years, the role of biologics in the management of RA, the number of available biologics, and the recommendations of use,…
Abstract Number: 2533 • 2014 ACR/ARHP Annual Meeting
Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren’s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting
Gabriela Hernandez-Molina¹, Carmen Ávila-Casado², Carlos Núñez-Álvarez³, Carlos Hernández-Hernández⁴, Maria Luisa Calderillo⁴, Martha Marroquín⁴, Claudia Recillas-Gispert⁵, Juanita Romero-Díaz³ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Pathology, University Health Network, Toronto Canada., Toronto, ON, Canada, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Dental Service, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁵Ophtalmology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To evaluate the feasibility and performance of the AECG and ACR Classification Criteria for Sjögren’s syndrome (SS) in patients with systemic autoimmune diseases. Methods:…
Abstract Number: 2532 • 2014 ACR/ARHP Annual Meeting
Characteristics of Primary Sjögren Syndrome in the Black Population of Martinique
Katlyne Polomat¹, Serge Arfi², Lauren Brunier-Agot³, Véronique Dehlinger⁴, Michel DeBandt³, Georges Jean Baptiste⁵ and Christophe Deligny⁶, ¹Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ³Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁴Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort De France - Martinique, Martinique, ⁵Rheumatology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Guadeloupe, ⁶Internal Medicine, CHU Fort de France, Fort de France, France
Background/Purpose: There is very limited data on the clinical, biological characteristics and evolution of primary Sjögren syndrome (pSS) in black patients of African origin. And…
Abstract Number: 2531 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon², Karn Wijarnpreecha³, Wisit Cheungpasitporn², Praveen Ratanasrimetha⁴ and Promporn Suksaranjit⁵, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Venous Thromboembolism in Patients with Sjogren's Syndrome: A Systematic Review and Meta-analysisBackground/Purpose: Venous thromboembolism (VTE) is a common medical problem with a significant…
Abstract Number: 2530 • 2014 ACR/ARHP Annual Meeting
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors
Karl Skriner¹, Jörg Hollidt², Gerd Burmester³ and Zoltan Konthur⁴, ¹Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Drug Response DX GmbH, Hennigsdorf, Germany
Background/Purpose One third of rheumatoid arthritis patients treated with biologicals targeting TNFα are therapy non-responders. We have earlier investigated the difference in seroreactivity of patients…
Abstract Number: 2529 • 2014 ACR/ARHP Annual Meeting
Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection
Kensei Tsuzaka^1,2, Yoko Akiyama² and Masayoshi Nagata¹, ¹Division of Rheumatology, Iruma Heart Hospital, Iruma, Saitama, Japan, ²Kaytee Bio, Co&Ltd, Funabashi, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of these biologics could…
Abstract Number: 2528 • 2014 ACR/ARHP Annual Meeting
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis
Yusuf Yazici¹, Chunqiao Luo² and Christopher Swearingen³, ¹New York University Hospital for Joint Diseases, New York, NY, ²University of Arkansas, Biostatistics, Little Rock, AR, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose NNT analysis is a useful tool for putting RCT efficacy results into perspective in patient care. For clinical decision making, the NNT is a…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 2526 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time
G. Avila¹, Arnald Alonso¹, María América López-Lasanta¹, Andrea Pluma-Sanjurjo², C. Diaz² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose The wide use of biological therapies (BTs) has clearly modified the therapeutic approach in rheumatoid arthritis (RA). One of the most commonly used tools…
Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Jonas K Eriksson¹, Heather Miller², Johan A Karlsson³, Ingemar F Petersson⁴, Sofia Ernestam⁵, Pierre Geborek³, Ronald F van Vollenhoven² and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…
Abstract Number: 2524 • 2014 ACR/ARHP Annual Meeting
Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration
Katerina Chatzidionysiou¹, Elisabeth Lie², Evgeny Nasonov³, Galina Lukina³, Merete Lund Hetland⁴, Ellen Hauge⁵, Karel Pavelka⁶, Cem Gabay⁷, Dan Nordström⁸, Helena Canhão⁹, Matija Tomsic¹⁰, Piet van Riel¹¹, Juan J. Gomez-Reino¹², Ioan Ancuta¹³, Tore K. Kvien¹⁴, Ronald F. van Vollenhoven¹⁵ and Saedis Saevarsdottir¹⁶, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³ARBITER, Institute of Rheumatology, Moscow, Russia, ⁴DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ⁸ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ⁹Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁰Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ¹¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ¹³“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ¹⁶Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Smoking has been identified as an important negative predictor of response to antirheumatic therapy. The aim of this study was to assess whether smoking…
Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Barbara Missler-Karger¹, Hans-Eckhard Langer², Mika Leinonen³ and Björn Pilström⁴, ¹Rheumatology consultant, Cologne, Germany, ²RHIO Research Institute, Düsseldorf, Germany, ³4Pharma AB, Stockholm, Sweden, ⁴TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].